Time filter

Source Type

Kortrijk, Belgium

Verschelden G.,VUB | Van Eetvelde E.,Dienst Oncologische Chirurgie | Djedaimi H.,Dienst Anatomopathologie | De Greve J.,Oncologisch Centrum
Tijdschrift voor Geneeskunde | Year: 2015

A leiomyosarcoma of the vena cava is a rare but potentially lethal tumor. It is more common in women around the 6th decade and is most frequently localised in the mid vena cava inferior. An oncological resection is the only way to provide a long term remission. Adjuvant therapy, based on radio and/or chemotherapy may prolong progression-free survival, but without hard evidence. Illustrated by a the medical history of a 51-year-old male patient, the current knowledge on leiomyosarcoma is discussed. Additionally, the specific characteristics of a primary leiomyosarcoma of the inferior vena cava are described. © 2015, Tijdschrift voor Geneeskunde. All rights reserved.

Schuler M.,University of Duisburg - Essen | Awada A.,Free University of Colombia | Harter P.,Dr. Horst Schmidt Kliniken GmbH | Canon J.L.,Grand HOpital de Charleroi | And 16 more authors.
Breast Cancer Research and Treatment | Year: 2012

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers. Afatinib has demonstrated preclinical activity in human epidermal growth factor receptor HER2 (ErbB2)-positive and triple-negative xenograft models of breast cancer, and clinical activity in phase I studies. This was a multicenter phase II study enrolling patients with HER2-negative metastatic breast cancer progressing following no more than three lines of chemotherapy. No prior epidermal growth factor receptor-targeted therapy was allowed. Patients received 50-mg afatinib once daily until disease progression. Tumor assessment was performed at every other 28-day treatment course. The primary endpoint was clinical benefit (≥B) for ≥4 treatment courses in triple-negative (≥ohort A) metastatic breast cancer (TNBC) and objective responses measured by Response Evaluation Criteria in Solid Tumors in patients with HER2-negative, estrogen receptor-positive, and/or progesterone receptorpositive breast cancer (≥ohort B). Fifty patients received treatment, including 29 patients in Cohort A and 21 patients in Cohort B. No objective responses were observed in either cohort. Median progression-free survival was 7.4 and 7.7 weeks in Cohorts A and B, respectively. Three patients with TNBC had stable disease for C4 treatment courses, one of them for 12 courses (median 26.3 weeks; range 18.9-47.9 weeks). The most frequently observed afatinib-associated adverse events (AEs) were gastrointestinal and skin-related side effects, which were manageable by symptomatic treatment and dose reductions. Afatinib pharmacokinetics were comparable to those observed in previously reported phase I trials. In conclusion, afatinib had limited activity in HER2-negative breast cancer. AEs were generally manageable and mainly affected the skin and the gastrointestinal tract. © The Author(s) 2012. This article is published with open access at Springerlink.com.

Coiffier B.,Service dhematologie | Radford J.,University of Manchester | Bosly A.,Clinique Universitaires Ucl Of Mont Godinne | Martinelli G.,Istituto Europeo di Oncologia | And 13 more authors.
British Journal of Haematology | Year: 2013

This international, multicentre phase II study was conducted to assess ofatumumab, a human anti-CD20 monoclonal antibody, in patients with relapsed/progressive diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous stem cell transplantation (TI) or who had relapse/progression after transplantation (PT). Eighty-one patients received ofatumumab 300 mg intravenously (IV) on Day 1, followed by seven weekly IV infusions of 1000 mg. Patients in the TI and PT groups had received a median of 3 (range, 1-7) and 5 (range, 2-7) prior therapies, respectively. One-third of patients did not respond to the last prior therapy, and 53% had failed two or more rituximab-containing therapies. Overall response rate was 13% for the TI group (seven partial responses) and 8% for the PT group (two complete responses). Median progression-free survival was 2·6 months, and median duration of response was 9·5 months. The most common Grade 3-4 adverse events were neutropenia (11%), leucopenia (6%), lymphopenia (6%) and thrombocytopenia (6%). Sixteen deaths have been reported, with disease progression as the most common cause of death. In conclusion, ofatumumab monotherapy was well tolerated and provided clinical benefit to some DLBCL patients in this study. This trial was registered at www.clinicaltrials.gov (NCT00622388). © 2013 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.

Wildiers H.,University Hospitals Leuven | Fontaine C.,Oncologisch Centrum | Vuylsteke P.,Sint Elisabeth Hospital | Martens M.,Sint Elisabeth Hospital | And 6 more authors.
Breast Cancer Research and Treatment | Year: 2010

The aim of this study is to test the hypothesis that antiangiogenic treatment with sunitinib consolidation can prolong remissions induced by taxane-based chemotherapy in women with metastatic breast cancer. The method involves a two-arm open-label (2:1 randomization) multicenter, randomized phase II trial evaluating the efficacy of sunitinib (arm A) versus no therapy (arm B) in patients with HER-2-negative metastatic breast cancer who achieved an objective response to taxane-based chemotherapy. The results of this study indicates that the primary endpoint of progression-free survival (PFS) ≥5 months was achieved in 10 of 36 patients (28%) in arm A and 4 of 19 patients (21%) in arm B. The median PFS was 2.8 and 3.1 months, respectively. A protocol amendment to the sunitinib dosing schedule was made because 53% (17/32) of patients treated at a starting dose of 50 mg (4 weeks on/2 weeks off) required dose reduction. Changing the starting dose to sunitinib 37.5 mg continuously resulted in dose reductions in 44% (7/16) of patients. Grades III-IV toxicity occurred in 69% of patients in arm A (fatigue 31%, musculoskeletal pain 11%, neutropenia and thrombopenia 8%) and 11% in arm B. The proof-of-principle study does not confirm the hypothesis that sunitinib consolidation therapy can lead to a predefined clinically relevant proportion of patients with PFS of ≥5 months after an objective response to taxanes. Furthermore, toxicity was significant. © 2010 Springer Science+Business Media, LLC.

De Brakeleer S.,Vrije Universiteit Brussel | De Greve J.,Oncologisch Centrum | Desmedt C.,Free University of Colombia | Joris S.,Oncologisch Centrum | And 4 more authors.
Clinical Genetics | Year: 2016

Triple-negative breast cancer (TNBC) accounts for 10-20% of all breast cancers (BCs), and conventional chemotherapy is the only effective systemic treatment. Germline BRCA1/2 mutations are found in approximately 15% of TNBC patients. In the past, we have documented pathogenic mutations in BARD1, a BRCA1 interacting protein, in families at high risk for BC. In this study, we have analyzed germline DNA from 61 estrogen receptor negative patients (of which 42 were TNBC) for the presence of mutations in the BRCA1, BRCA2 and BARD1 gene. BRCA1/2 mutations were found in 8 out of 42 (19%) TNBC patients, but not in the ER-/HER2+ cohort. We also found four good candidate pathogenic BARD1 mutations in the TNBC cohort, including two protein-truncating mutations (p.Gln564Ter and p.Arg641Ter). Our data suggest that TNBC patients are enriched for pathogenic BARD1 germline mutations as compared to control samples and high BC risk families. Ten of the 42 investigated TNBC patients carry a BRCA pathway mutation (in BRCA1, BRCA2 or BARD1) rendering them susceptible to homologous recombination deficiency. These patients should become eligible for exploring the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors. © 2016 John Wiley & Sons A/S.

Discover hidden collaborations